title: The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema.
abstract: OBJECTIVE
  To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for diabetic macular oedema (DMO) from a multicentre database.
  
  
  METHODS
  Structured clinical data were anonymised and extracted from an electronic medical record from 19 participating UK centres: age at first injection, ETDRS visual acuity (VA), number of injections, ETDRS diabetic retinopathy (DR) and maculopathy grade at baseline and visits. The main outcomes were change in mean VA from baseline, number of injections and clinic visits and characteristics affecting VA change and DR grade.
  
  
  RESULTS
  Data from 12 989 clinic visits was collated from baseline and follow-up for 3103 eyes. Mean age at first treatment was 66 years. Mean VA (letters) for eyes followed at least 2 years was 51.1 (SD=19.3) at baseline, 54.2 (SD: 18.6) and 52.5 (SD: 19.4) at 1 and 2 years, respectively. Mean visual gain was five letters. The proportion of eyes with VA of 72 letters or better was 25% (baseline) and 33% (1 year) for treatment naïve eyes. Eyes followed for at least 6 months received a mean of 3.3 injections over a mean of 6.9 outpatient visits in 1 year.
  
  
  CONCLUSIONS
  In a large cohort of eyes with DMO treated with ranibizumab injections in the UK, 33% of patients achieved better than or equal to 6/12 in the treated eye at 12 months compared with 25% at baseline. The mean visual gain was five letters. Eyes with excellent VA at baseline maintain good vision at 18 months.
authors.affiliation: Department of Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK.|Institute of Ophthlamology, London, UK.
authors.forename: Catherine
authors.initials: C
authors.lastname: Egan
authors.affiliation: City University, London, London, UK.
authors.forename: Haogang
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of Ophthalmology, University of Washington, Seattle, USA.
authors.forename: Aaron
authors.initials: A
authors.lastname: Lee
authors.affiliation: Department of Medical Retina, Moorfields Eye Hospital, London, UK.|Department of Cell Biology, UCL Institute of Ophthalmology, London, UK.
authors.forename: Dawn
authors.initials: D
authors.lastname: Sim
authors.affiliation: Department of Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
authors.forename: Danny
authors.initials: D
authors.lastname: Mitry
authors.affiliation: Bristol Eye Hospital, Bristol, UK.
authors.forename: Clare
authors.initials: C
authors.lastname: Bailey
authors.affiliation: Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.
authors.forename: Robert
authors.initials: R
authors.lastname: Johnston
authors.affiliation: Queens University, Belfast, UK.
authors.forename: Usha
authors.initials: U
authors.lastname: Chakravarthy
authors.affiliation: University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
authors.forename: Alastair
authors.identifier: http://orcid.org/0000-0001-7849-0087
authors.initials: A
authors.lastname: Denniston
authors.affiliation: Department of Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK.|Institute of Ophthlamology, London, UK.
authors.forename: Adnan
authors.initials: A
authors.lastname: Tufail
authors.affiliation: Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, UK.
authors.forename: Rehna
authors.initials: R
authors.lastname: Khan
authors.affiliation: Manchester Royal Eye Hospital, Manchester, UK.
authors.forename: Sajjad
authors.initials: S
authors.lastname: Mahmood
authors.affiliation: Eye Department, Frimley Park Hospital, Frimley, UK.
authors.forename: Geeta
authors.initials: G
authors.lastname: Menon
authors.affiliation: Hinchingbrooke Health Care NHS Trust, Huntingdon, Cambridgeshire, UK.
authors.forename: Toks
authors.initials: T
authors.lastname: Akerele
authors.affiliation: Department of Ophthalmology, Hull Royal Infirmary, Hull, UK.
authors.forename: Louise
authors.initials: L
authors.lastname: Downey
authors.affiliation: Leeds, UK.
authors.forename: Martin
authors.initials: M
authors.lastname: McKibbin
authors.affiliation: Mid Yorkshire Hospitals NHS Trust, Yorkshire, UK.
authors.forename: Atul
authors.initials: A
authors.lastname: Varma
authors.affiliation: Moorfields Eye Hospital NHS Foundation Trust, London, London, UK.
authors.forename: Aires
authors.initials: A
authors.lastname: Lobo
authors.affiliation: Northern Devon Healthcare NHS Trust, Barnstaple, Devon, UK.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Wilkinson
authors.affiliation: Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, Peterborough, UK.
authors.forename: Alan
authors.initials: A
authors.lastname: Fitt
authors.affiliation: Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
authors.forename: Christopher
authors.initials: C
authors.lastname: Brand
authors.affiliation: Department of Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
authors.forename: Marie
authors.initials: M
authors.lastname: Tsaloumas
authors.affiliation: Department of Ophthalmology, Warrington and Halton Hospitals NHS Foundation Trust, Warrington, UK.
authors.forename: Kaveri
authors.initials: K
authors.lastname: Mandal
authors.affiliation: Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.
authors.forename: Vineeth
authors.initials: V
authors.lastname: Kumar
authors.affiliation: Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, UK.
authors.forename: Salim
authors.initials: S
authors.lastname: Natha
authors.affiliation: Division of Optometry & Visual Science, City University, London, UK.
authors.forename: David
authors.initials: D
authors.lastname: Crabb
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000008:administration & dosage*; D011932:Reading; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab
keywords: Macula; Public health; Retina; Treatment Medical; Treatment Surgery